FDA Approves Non-effective New Alzheimer’s Drug Despite Their Own Doctors Recommending AGAINST It

Big Pharma has been trying to create a blockbuster drug for the very lucrative Alzheimer's Disease for more than a decade. But they have repeatedly failed, mainly because they start with the wrong presuppositions on the cause of Alzheimer's, basing it on "genetics" instead of environmental causes. The over 55 age population has always been a cash cow for Big Pharma, as the most profitable drug of all time was Pfizer's Lipitor, a statin drug that artificially lowers one's cholesterol. Prior to its patent expiring at the end of 2011, no other drug in human history had racked up more sales than this one single drug, as their advertising campaign against cholesterol resulted in doctors placing nearly one out of every four people over the age of 55 on statin drugs to lower their cholesterol. But 25% of our body's cholesterol resides in our brains, so there have been honest researchers over the years, such as Dr. Stephanie Seneff at MIT, who have linked low cholesterol to a rise in Alzheimer's Disease. And so it is no surprise that coconut oil, demonized by Big Pharma, the USDA, the FDA and just about every other regulatory agency in the U.S. since the 1970s, can provide dramatic improvement to Alzheimer's Disease and other forms of dementia, often with dramatic results. See our body of research provided over the years on coconut oil, along with amazingly dramatic testimonials for curing Alzheimer's at CoconutOil.com. We have covered all the previous failures of Big Pharma to produce a drug to treat Alzheimer's over the years, but just this week the FDA finally approved a drug for the treatment Alzheimer's Disease. But as reporter Andrew Joseph of Stat News writes, the FDA did so in spite of the fact that their own 11 doctor expert panel had 10 of those doctors state that "there was not enough evidence to show it could slow cognitive decline," and the 11th doctor voted “uncertain.” And now one of those doctors, Neurologist Joel Perlmutter of Washington University in St. Louis, has resigned.